Cabometyx 60 mg Tablet

Description

Cabometyx 60 mg Tablet contains cabozantinib, an oral targeted anticancer medicine classified as a tyrosine kinase inhibitor (TKI). It is used in the management of certain advanced cancers by blocking multiple signaling pathways that tumors use to grow and spread. Cabometyx is commonly prescribed for conditions such as advanced renal cell carcinoma (kidney cancer), hepatocellular carcinoma (liver cancer), and certain thyroid cancers, depending on regulatory approvals and clinical recommendations. Cabozantinib works by targeting proteins involved in tumor growth, blood vessel formation, and cancer cell survival. By inhibiting these pathways, it may help slow disease progression when used as prescribed by a qualified healthcare professional. Treatment with Cabometyx is typically part of a comprehensive oncology care plan and requires regular monitoring by a physician, including blood tests

Benefits

• Targets multiple cancer-related pathways, including MET, VEGFR, and AXL

• Oral therapy that may allow outpatient cancer management

• May help slow tumor growth and spread in certain cancers

• Used in advanced-stage cancers where targeted therapy is appropriate

• Part of modern precision oncology treatment approaches

Indications and Usage

Cabometyx (cabozantinib) may be prescribed for:

• Advanced Renal Cell Carcinoma (RCC)

• Hepatocellular Carcinoma (HCC) in patients previously treated with sorafenib

• Differentiated thyroid cancer (DTC) that has progressed after prior therapy

• Other oncology uses where approved by regulatory authorities

Use is determined by an oncologist based on the patient’s diagnosis, disease stage, and prior treatments.

How it Works

Cabozantinib works by inhibiting several tyrosine kinase receptors, including MET, VEGFR, and AXL, which are involved in tumor growth, angiogenesis (formation of new blood vessels), and cancer cell survival. Many cancers rely on these signaling pathways to maintain blood supply and spread to other tissues.

By blocking these enzymes, cabozantinib may reduce tumor cell proliferation and disrupt the blood vessels that supply nutrients to tumors. This targeted approach can help slow disease progression in some patients when used as prescribed and monitored by a healthcare professional.

Dosage & Administration

Dosage & Administration

• Cabometyx tablets are taken orally, usually once daily unless otherwise directed by a healthcare professional.

• Tablets should be swallowed whole with water.

• Do not crush, split, or chew the tablets.

• The medicine is typically taken on an empty stomach (avoid food for at least 2 hours before and 1 hour after the dose, unless instructed otherwise).

• Dosage adjustments may occur based on tolerance, side effects, or clinical response.

• Treatment duration is determined by the treating oncologist.

Side Effects

Common side effects

• Fatigue

• Diarrhea

• Decreased appetite

• Nausea or vomiting

• Weight loss

• High blood pressure

• Hand–foot syndrome (palmar-plantar erythrodysesthesia)

• Mouth sores

Serious side effects

• Severe bleeding

• Gastrointestinal perforation or fistula

• Severe hypertension

• Liver function abnormalities

• Blood clots

• Delayed wound healing

Patients should seek medical attention if serious symptoms occur.

Warning and Precaution

• Risk of severe bleeding events

• Possible gastrointestinal perforation or fistula formation

• High blood pressure requiring monitoring

• Potential liver toxicity

• Risk of blood clots or thromboembolic events

• Delayed wound healing; inform healthcare providers before surgery

• May cause severe diarrhea or dehydration

• Pregnancy should be avoided during treatment

Patient Guidance

• Take the medication exactly as prescribed by your oncologist

• Attend regular monitoring appointments and laboratory tests

• Report symptoms such as severe bleeding, chest pain, or severe diarrhea

• Inform your doctor about all medications, vitamins, and herbal products

• Avoid grapefruit and grapefruit products, which may affect drug levels

• Maintain proper hydration during treatment

• Store medication according to labeled instructions

Clinical Trial & Approvals

Cabozantinib has been evaluated in several major clinical trials for cancer treatment. Studies such as METEOR and CABOSUN trials demonstrated improved progression outcomes in certain patients with advanced renal cell carcinoma. Based on these and other studies, cabozantinib has received approvals from regulatory agencies including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for specific oncology indications.

References

1. U.S. Food and Drug Administration (FDA) – Cabometyx Prescribing Information
   https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/208692s003lbl.pdf

2. FDA Drug Approval Information – Cabozantinib (Cabometyx)
   https://www.fda.gov/drugs/resources-information-approved-drugs/cabozantinib-cabometyx

3. Drugs.com – Cabometyx (Cabozantinib) Drug Information
   https://www.drugs.com/history/cabometyx.html

4. National Cancer Institute (NCI) – Cabozantinib Overview
   https://www.cancer.gov/about-cancer/treatment/drugs/cabozantinib

5. ClinicalTrials.gov – Cabozantinib Clinical Studies
   https://clinicaltrials.gov/search?cond=&term=cabozantinib

6. Official HCP Website – Cabometyx (Exelixis/Ipsen)
   https://www.cabometyxhcp.com

7. Cabozantinib Drug Overview (Background & Mechanism)
   https://en.wikipedia.org/wiki/Cabozantinib